source
- New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warnA new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
- Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer dealEli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…